RecruitingPhase 2NCT07033026
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
Sponsor
NGM Biopharmaceuticals, Inc
Enrollment
136 participants
Start Date
Jun 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Documented active diagnosis of colorectal cancer.
- Cachexia defined by Fearon criteria of weight loss.
- Signed informed consent.
Exclusion Criteria3
- Current active reversible causes of decreased food intake.
- Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
- Have cachexia caused by other reasons.
Interventions
DRUGNGM120 Q4W
NGM120 given subcutaneously every 4 weeks
DRUGNGM120 Q8W
NGM120 given subcutaneously every 8 weeks
DRUGPlacebo given
Placebo given subcutaneously every 4 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07033026
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT0691707910 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location